
    
      Exenatide is a short-acting Glucagon-Like Peptide receptor 1 (GLP-1 R) agonist.

      The clinical trial is conducted in10 healthy volunteers. Each subject receives one dose of
      subcutaneous exenatide (10 Î¼g). After that, hormonal and physiological changes are measured
      during two hours. The blood samples are taken in 30-minute intervals.

      The primary endpoint is peak value of cortisol achieved during the 2 hours after drug
      administration.
    
  